Overview
Tesamorelin is a synthetic growth hormone-releasing hormone analog studied for its effects on visceral adipose tissue, body composition, lipid metabolism, and liver fat in HIV-associated lipodystrophy and NAFLD research.
Mechanism of Action
Tesamorelin stimulates GHRH receptors in the pituitary, increasing endogenous growth hormone release and IGF-1 signaling. Research suggests this may promote lipolysis, reduce visceral fat, and influence hepatic fat metabolism
Compound Information
Stability Information
- Type: Synthetic GHRH analog
- CAS Number: 218949-48-5
- Molecular Formula: C221H366N72O67S
- Amino Acids: 44
- Category: Growth hormone-releasing hormone analog
- Research areas: visceral fat, lipodystrophy, liver fat, metabolic markers
- Room temperature stable (short-term)
- Protect from light
- Avoid repeated freeze-thaw cycles
- Lyophilized: Store at -20°C
- Reconstituted: Store at 2-8°C
Published Studies
- Metabolic effects of a growth hormone-releasing factor in HIV patients.
- Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation.
- Pooled phase-3 analysis of tesamorelin in ART-treated HIV patients.
- Long-term safety and effects of tesamorelin.
- Placebo-controlled dose-ranging study of growth hormone-releasing factor.
- Tesamorelin review for HIV-associated lipodystrophy.
- Effect of tesamorelin on visceral fat and liver fat.
- Reduction in visceral adiposity and metabolic markers.
- Effects of tesamorelin on NAFLD in HIV.
- Effects of tesamorelin on hepatic transcriptomic signatures
Information provided for educational and research reference purposes only. Studies listed are third-party publications and do not constitute medical advice.
